
Adipotide
Adipotide (FTPP / Prohibitin-TP01)
Also called FTPP, prohibitin-targeting peptide, adipotide
Targeting the blood supply of fat tissue
Adipotide takes a different route to fat loss: instead of touching appetite, it targets the blood vessels feeding fat tissue and kills them, so the fat starves. Preclinical studies showed large fat loss and kidney damage together, and it has never completed a human efficacy trial.
An experimental peptide that takes a different approach to fat loss: instead of suppressing appetite, it targets the blood vessels that feed white fat tissue, triggering their die-off so fat cells lose their supply. Results in preclinical studies were striking, and so was kidney toxicity, which is why it never advanced in humans beyond a small phase 1.
- Half-life
- Short, in the range of hours
- Route studied
- Subcutaneous injection (studies)
- Status
- Not FDA-approved
Early research, mostly in the lab so far
What Adipotide has been studied for
The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.
- Fat loss
- The reason people look it up. In preclinical work it produced fast, substantial fat loss without appetite suppression, alongside kidney damage. Not tested for fat loss in people.
Mechanism of Action
How Adipotide works
Adipotide is a targeting peptide fused to a pro-apoptotic sequence:
- Homing to fat blood vessels. The targeting portion binds prohibitin and ANXA2 markers on the blood vessels that supply white fat tissue.
- Triggered vessel death. The attached pro-apoptotic peptide then induces programmed death of those vessels, cutting off the fat's blood supply.
- Fat-cell shrinkage. Deprived of supply, fat cells shrink and are resorbed, independent of appetite.
- Known toxicity limit. Preclinical studies showed rapid fat loss and also dose-related kidney effects, which halted human development.
Adipotide side effects: what studies reported
Here the side effects are the story rather than a footnote. The kidney signal in preclinical studies is why the compound stalled.
The one that matters
- Kidney damage. It showed up in the preclinical work alongside the weight loss people quote, and it was dose-related
Also reported
- Dehydration
- Changes in urination
- Injection-site reactions
Source: Preclinical studies and a small phase 1 in men with obesity and prostate cancer. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about Adipotide belong with a licensed clinician who knows your history.
Your Genetics & Adipotide
The genes involved in how Adipotide works
Adipotide works through the receptors these genes build, and the genes vary from person to person. Researchers have linked some of that variation to differences in how people respond. A DNA report tells you which versions you carry.
FTO · ••
The FTO risk allele is associated with higher fat mass and appetite in population studies. No study has tested any genotype with adipotide.
ADRB3 · ••
The Trp64Arg variant has been studied for its association with fat metabolism and body weight, with mixed results. Pathway context only.
PPARG · ••
The Pro12Ala variant has been associated with fat-cell formation and insulin sensitivity in human studies. Pathway context only.
LEPR · ••
The Gln223Arg variant in the leptin receptor has been studied for its association with body weight, with mixed results. Pathway context only.
The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.
Which of these variants do you carry?
Your report reads the DNA file you already have against this research.
Access
Access and legal status
Adipotide is not an FDA-approved drug. Products sold online as “research chemicals” are labelled not for human use, and FDA treats them as unapproved drugs when they are marketed for people. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.
Your DNA and Adipotide: see which of the variants studied alongside it you carry, and what that research does and does not show. Read my DNA, $99 →
Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.
Worth knowing about Adipotide
Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.
- The kidney problem is the headline, not a footnote
- Every impressive number quoted for this compound comes from the same studies that found the kidney signal. They are not separable, and there is no human dose known to avoid it.
- No completed human trial
- There is no established dose and no known safety margin in people. Anything quoted as a human protocol is extrapolated from preclinical work.
Last updated
Frequently Asked Questions
How is Adipotide different from GLP-1 drugs?
GLP-1 drugs like semaglutide suppress appetite. Adipotide works through a different mechanism: it targets and destroys the blood vessels feeding white fat tissue, so fat cells lose their supply and shrink. It does not act on hunger signalling.
What is known about adipotide's safety?
Preclinical studies showed dose-related kidney toxicity alongside the fat loss, and development stalled after a small phase 1. There are no human safety data establishing a safe dose, and it is not an approved medicine.
Does genetics affect Adipotide response?
No study has tested whether any genotype changes response to adipotide. FTO, ADRB3, PPARG and LEPR variants have been associated with fat mass or fat metabolism in human studies. A DNA report can show which versions you carry and what that research does and does not show.
Your DNA and Adipotide
What the research says about your variants.
The report
Which Adipotide variants do you carry?
Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show.
Read my DNA, $99